Science

Zydus Cadila gets USFDA nod for low blood pressure drug

PTI New Delhi | Updated on February 19, 2021

Droxidopa to be manufactured at facility in SEZ, Ahmedabad

Zydus Cadila said on Friday that it has received final approval from the US health regulator to market Droxidopa capsules, used to treat low blood pressure.

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Droxidopa capsules in the strength of 100 mg, 200 mg, and 300 mg, Cadila Healthcare said in a regulatory filing.

Zydus Cadila is part of the Cadila Healthcare group.

Zydus Cadila has more orders for Covid-19 vaccine than it can make: Report

312 approvals

Droxidopa works by constricting (narrowing) the blood vessels and increasing blood pressure. It is used to treat low blood pressure that causes severe dizziness or a light-headed feeling.

The company further said that Droxidopa is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).

Zydus Cadila gets USFDA nod to market cream for treating skin conditions

The newly approved medication will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 312 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.

Shares of Cadila Healthcare were trading 1.51 per cent lower at ₹460.45 apiece on BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 19, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.